PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Conditions: Triple Negative Breast Cancer Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Pembrolizumab; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Olaparib; Drug: Capecitabine Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Conditions: Nasopharyngeal Carcinoma Interventions: Drug: PD-1 blocking antibody; Drug: Gemcitabine; Drug: Cisplatin (80 mg/m2); Radiation: Reduced-dose Intensity-modulated radiotherapy; Radiation: Conventional-dose Intensity-modulated radiotherapy; Drug: Cisplatin (100 mg/m2); Drug: Capecitabine Sponsors: Sun Yat-sen University; Jiangsu Hengrui Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
SCRT Followed by Fruquintinib Plus Adebrelimab and CAPOX
Conditions: Locally Advanced Rectal Cancer Interventions: Drug: Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine Sponsors: Wuhan Union Hospital, China; Renmin Hospital of Wuhan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
Conditions: Breast Cancer; Triple Negative Breast Cancer Interventions: Drug: Adebrelimab; Drug: Vinorelbine; Drug: Cyclophosphamide (tablet); Drug: Capecitabine Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials
HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer
Conditions: Pancreatic Cancer Interventions: Drug: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate; Drug: gemcitabine; capecitabine Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Conditions: HER2-positive Breast Cancer; Advanced Breast Cancer Interventions: Drug: Pyrotinib; Drug: Trastuzumab; Drug: Taxanes; Drug: Capecitabine Sponsors: Hebei Medical University Fourth Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
Conditions: Rectal Cancer Interventions: Drug: liposomal irinotecan; Drug: Capecitabine; Radiation: Radiation threapy Sponsors: Hebei Medical University Fourth Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Conditions: Advanced Solid Tumors Interventions: Drug: JS105; Drug: Fulvestrant injection; Drug: Dalpiciclib Isetionate Tablets; Drug: Toripalimab Injection; Drug: Paclitaxel for Injection (Albumin Bound); Drug: Fluzoparib Capsules; Drug: Pyrotinib Maleate Tablets; Drug: Capecitabine Tablets Sponsors: Risen (Suzhou) Pharma Tech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2024 Category: Research Source Type: clinical trials
PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC
Conditions: Colorectal Cancer; RAS Mutation; Colorectal Neoplasms; Microsatellite Stable Colorectal Carcinoma Interventions: Drug: oxaliplatin+capecitabine+bevacizumab+PD-1 antibody Sponsors: Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced, and Unresectable G/GEJ Cancer
Conditions: Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma Interventions: Drug: ASKB589; Drug: Oxaliplatin; Drug: Capecitabine; Drug: Tislelizumab; Drug: Placebo Sponsors: AskGene Pharma, Inc.; Jiangsu Aosaikang Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Conditions: Rectal Cancer Interventions: Drug: Leucovorin; Drug: Oxaliplatin; Drug: Fluoruracil; Drug: Capecitabine; Radiation: Radiation Sponsors: Canadian Cancer Trials Group; Alliance for Clinical Trials in Oncology; ECOG-ACRIN Cancer Research Group; NRG Oncology; SWOG Cancer Research Network Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials
Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
Conditions: Locally Advanced Rectal Cancer Interventions: Radiation: node-sparing short-course radiotherapy; Drug: Sintilimab; Drug: Capecitabine; Drug: Oxaliplatin; Procedure: TME surgery; Procedure: watch and wait Sponsors: Jinhua Central Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
Phase II Study of Radiotherapy Plus Envolizumab and Capecitabine in Locally Advanced Pancreatic Cancer
Conditions: Pancreatic Cancer; Radiotherapy; Envolizumab; Capecitabine Interventions: Other: Radiotherapy Plus Envolizumab and Capecitabine Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2024 Category: Research Source Type: clinical trials
Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage
Conditions: Gastric Cancer Interventions: Drug: Oxaliplatin and capecitabine/ S-1 and capecitabine Sponsors: The First Affiliated Hospital of Zhengzhou University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
Conditions: CRC; Metastatic Colorectal Cancer; Metastatic Colorectal Adenocarcinoma Interventions: Drug: Experimental; Drug: Active Comparator Sponsors: Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
